Apotex restraint
December 16, 2011
AN interlocutory injunction
granted by an Australian Duty
Judge is now in place restraining
Apotex from further marketing of
its rosuvastatin products.
According to Apotex, the
interlocutory rosuvastatin
injunction is in place until “further
order of the court” and prevents
the company from selling,
supplying, offering to sell or
supply, soliciting or take orders for,
or advertising or promoting its
rosuvastatin products.
“The imposition of an
interlocutory injunction is
extremely disappointing,” an
Apotex statement said.
“The hearing was listed on short
notice and the injunction was
imposed on the basis of the limited
evidence that was before the court
at the hearing.
“Apotex remains confident that
the patents are invalid and not
infringed and that it will ultimately
prevail in this litigation,” the
statement added.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Dec 11To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Dec 11
